U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07231211) titled 'A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors' on Nov. 13.
Brief Summary: This study is an open, multicenter Phase I/II clinical trial, divided into two stages: dose exploration (including dose escalation and dose extension) and efficacy extension.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
DRUG: SHR-4610 Injection
SHR-4610 injection in different dose.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd
Published by HT Digital Content Services with permission from Health Daily Digest....